Evotec expands GMP sterile pharmaceutical manufacturing facility

German drug discovery company Evotec has expanded its sterile pharmaceutical manufacturing facility in Glasgow, Scotland.

The company has doubled its capacity for the aseptic GMP manufacture of pharmaceuticals to be used in clinical trials, with the new facility being operational with immediate effect.

Evotec's formulations business is a niche provider of contract pharmaceutical development services for the development of formulations of pharmaceuticals intended for parenteral administration and the manufacture of formulated drugs for use in Phase I and Phase II clinical trials.

It has particular expertise in the development of lyophilised formulations and the subsequent sterile manufacture of those formulated drugs. In addition, it has dedicated facilities to assist in the development of cytotoxic (cytotstatic) pharmaceuticals.

The expansion of the facilities is in response to the demand for clinical supplies of liquid and lyophilised drug product. The additional facilities will allow Evotec to shorten the lead-time to access its manufacturing capabilities and will therefore accelerate the progression of Evotec's clients" drugs into the clinical stage of drug development.